Sign In
Buy AVXL
$2.65
-0.140 (-5.03%)
At Close: Jun 03, 2026
Anavex Life Sciences to Present at the Dawson James Securities 6th Annual Conference
07:00am, Friday, 15'th Oct 2021
NEW YORK, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeu
Anavex Life Sciences Announces Participation at 5th Pharma Pricing, Reimbursement & Market Access 2021
09:30am, Monday, 27'th Sep 2021
NEW YORK, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therape
Anavex Life Sciences Announces Uplisting to the NASDAQ Global Select Market®
07:00am, Monday, 27'th Sep 2021
NEW YORK, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therape
Anavex Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference
07:00am, Monday, 20'th Sep 2021
NEW YORK, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therape
Anavex Life Sciences: Still Room To Run
08:11am, Sunday, 29'th Aug 2021
Lead candidate ANAVEX2-73 has shown impressive results in placebo-controlled Phase 2 studies in Parkinson's disease and Rett syndrome. Ongoing studies in Rett syndrome could lead to a filing in 2022 i
Anavex Life Sciences Corp. (AVXL) CEO Christopher Missling on Q3 2021 Results - Earnings Call Transcript
11:18pm, Thursday, 12'th Aug 2021
Anavex Life Sciences Corp. (AVXL) CEO Christopher Missling on Q3 2021 Results - Earnings Call Transcript
Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Results
07:00am, Thursday, 12'th Aug 2021
NEW YORK, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeu
Anavex Life Sciences to Participate in the BTIG Virtual Biotechnology Conference 2021
07:00am, Wednesday, 04'th Aug 2021
NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeu
Detours In The Golden Age Of Alzheimer's Drug Stock Investments
02:58pm, Tuesday, 03'rd Aug 2021
Biogen's Aduhelm performed no better than placebo in non-ApoE4 carriers and only slightly slowed down the progression of Alzheimer's disease in ApoE4 carriers.
Here's Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday
03:30pm, Thursday, 29'th Jul 2021
A clinical-trial flop for Annovis Bio is reminding investors that developing new drugs for Alzheimer's disease is an extremely risky business.
Anavex Life's Stock Declines Despite Data Shows Alzheimer's Candidate Prevent Abeta-Induced Cognitive Decline In Animal Study
10:08am, Thursday, 29'th Jul 2021
Anavex Life Sciences Corp (NASDAQ: AVXL) has reported new preclinical data for its Alzheimer's candidate, ANAVEX2-73 (blarcamesine). Pre-treatment with blarcamesine repeated once daily for one week
Anavex (AVXL) to Report Q3 Earning: What's in the Cards?
02:35pm, Tuesday, 27'th Jul 2021
On Anavex's (AVXL) earnings call for the fiscal third quarter, investor focus will mainly be on the company's progress with its lead investigational candidate for Alzheimer's disease.
3 Biotech Penny Stocks To Watch Seeing Explosive Gains In 2021
12:17pm, Wednesday, 21'st Jul 2021
Are biotech penny stocks on your watch list in 2021? The post 3 Biotech Penny Stocks To Watch Seeing Explosive Gains In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS
Anavex: A Catalyst-Rich Year
03:36am, Monday, 05'th Jul 2021
Anavex Life Sciences Corporation conducts clinical trials for its small Anavex 2-73 (blarcamesine) and Anavex 3-71 (AF710B) molecules. The biotech has a rich development pipeline aimed at neurodegener
Why This Anavex Life Sciences Analyst Is Lifting Their Price Target
03:44pm, Monday, 28'th Jun 2021
A Cantor Fitzgerald analyst is incrementally bullish on shares of Anavex Life Sciences, Corp (NASDAQ:AVXL) after the release of Phase 2 data for the company's lead candidate. The Anavex Analyst: Charl
